Posted by Michael Wonder on 27 Aug 2021
Argenx announces validation of European marketing authorisation application for efgartigimod in generalised myasthenia gravis
25 August 2021 - Validation initiates formal evaluation of application which started on 19 August 2021; decision expected mid-2022.
Argenx today announced that it has submitted, and the European Medicines Agency has validated, the marketing authorization application for the Company’s investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis.
